Nurix Therapeutics Inc [NRIX] stock prices are up 8.84% to $22.03 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The NRIX shares have gain 13.50% over the last week, with a monthly amount glided 43.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on March 09, 2023, and set its price target to $20. On February 28, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $25 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $11 on October 11, 2022. Wells Fargo upgraded its rating to a Overweight but $25 remained the price target by the analyst firm on May 31, 2022. Wells Fargo started tracking with a Equal Weight rating for this stock on February 10, 2022, and assigned it a price target of $28. In a note dated December 29, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $62 on this stock.
The stock price of Nurix Therapeutics Inc [NRIX] has been fluctuating between $4.22 and $22.44 over the past year. Currently, Wall Street analysts expect the stock to reach $27.5 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $22.03 at the most recent close of the market. An investor can expect a potential return of 24.83% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
The Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 80.89M for trailing twelve months, representing a surge of 30.74%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -2.87%, Pretax Profit Margin comes in at -2.65%, and Net Profit Margin reading is -2.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.68 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.80 points at the first support level, and at 19.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.02, and for the 2nd resistance point, it is at 24.02.
Ratios To Look Out For
It’s worth pointing out that Nurix Therapeutics Inc [NASDAQ:NRIX]’s Current Ratio is 2.86. On the other hand, the Quick Ratio is 2.86, and the Cash Ratio is 1.45. Considering the valuation of this stock, the price to sales ratio is 17.53, the price to book ratio is 6.41.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Jul 01 ’24 when 5760.0 shares were sold. Chief Financial Officer, van Houte Hans completed a deal on Jun 20 ’24 to sell 20000.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 1864.0 shares on Jun 13 ’24.
